ImmuniT Research Inc. has signed a license agreement with “Sysmex Corporation” regarding exclusive rights that anticipates the effect of immuno-checkpoint inhibitors by blood test.

PRESS RELEASE “ImmuniT Research Inc. has signed a license agreement with “Sysmex Corporation” regarding exclusive rights that anticipates the effect of immuno-checkpoint inhibitors by blood test.”

Sysmex and ImmuniT Research Enter Agreement on the Sublicensing of Patent Related to a Diagnosing Method for Predicting Efficacy of Immune Checkpoint Inhibitors